SynapCyte is a regenerative bio-therapeutic company focused on research, development, regulatory approval and commercialization of therapies for the treatment of Alzheimer’s and Parkinson’s diseases.

SynapCyte’s patented technologies are designed to treat Alzheimer’s and Parkinson’s disease by stimulating in the patient’s brain the production and proliferation of the endogenous (pre-existing) human stem cells (HNSC’s), thus regenerating neural (brain) cells lost in patient’s suffering from these neurodegenerative diseases.

Why Alzheimer's Disease?

With an aging baby boomer population, this disease is reaching epidemic proportions within the US, afflicting 5.5 million Americans in 2018, and this number is projected to double over the next 10 years.

Why Parkinson's Disease?

Parkinson’s is a debilitating neurodegenerative disease affecting more than 1 million Americans with the addition of 60,000 new cases annually.

Meet Our Team

Find out more about SynapCyte and its’ contributors.

Latest News

SynapCyte was featured in Centennial Health Special Edition 2018 Single Issue ALZHEIMER'S - NEW HOPE FOR A CURE

SynapCyte and its lead scientific officer, Dr. Kiminobu Sugaya were featured in the article “A FUTURE WITHOUT AD”. The article…

June 21, The Orlando Sentinel publishes story on SynapCyte

UCF spin-off company hunts cure for Alzheimer’s disease By Naseem S. Miller – Contact Reporter More than three decades ago,…

Meet the first 5 startups in UCF's new $4M Lake Nona Life Sciences Incubator

The University of Central Florida’s new 10,000-square-foot Lake Nona Life Sciences Incubator, which opened May 10 on the second floor…